Clinical trials: Acute Myeloid Leukemia, in Relapse
CD33 Positive Acute Myelogenous Leukemia
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
An expanded access/compassionate use protocol that allows access to Mylotarg for relapsed/refractory AML CD33 positive patients in the USA. Contact: B1761026@iconplc.com
- Trial name
- AML (NCT02312037)
- Testing
- Antibody Drug Conjugate Chemotherapeutic
- Where
- 142 sites in United States
- Sponsor
- Pfizer
Acute Myeloid Leukemia (AML)
CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML.
- Trial name
- CART123 (NCT07464951)
- Testing
- Anti-CD123 LV redirected T cells (CART123), Ruxolitinib (JAKAVI®)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stephan Grupp MD PhD
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that is untreated or has come back (relapsed).
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
- Trial name
- NCT03661307
- Testing
- Decitabine, Quizartinib, Venetoclax
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelocytic, Acute
Infection and Tumour Antigen Cellular Therapy
This study is to test a new therapy for patients with acute myeloid leukaemia who are undergoing blood stem cell transplant. In this study, the investigators will take a small number of your immune cells whose normal function is…
- Trial name
- INTACT-WT1 (NCT02895412)
- Testing
- Donor-derived WT1-CTL and P-CTL
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Sydney
Leukemia, Myeloid, Acute, Lymphoblastic Leukemia, Acute
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)
Participants with acute myelogenous leukemia (AML) will be randomized to SCH 727965 or gemtuzumab ozogamicin. All participants with acute lymphoblastic leukemia (ALL) will receive SCH 727965.
- Trial name
- NCT00798213
- Testing
- SCH 727965, Gemtuzumab ozogamicin
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
This phase II trial studies how well enasidenib works in treating in patients with acute myeloid leukemia with an IDH2 gene mutation that has come back or has not responded to treatment.
- Conditions
- Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level, IDH2 Gene Mutation, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT03881735
- Testing
- Enasidenib, Hematopoietic Cell Transplantation
- Where
- 2 sites in United States
- Sponsor
- Roswell Park Cancer Institute
Acute Promyelocytic Leukemia
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
This is a Phase II, open-label, non-randomized study to evaluate the safety, efficacy, and pharmacokinetics of tamibarotene in adult patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with…
- Trial name
- STAR-1 (NCT00520208)
- Testing
- Tamibarotene
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- CytRx
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Adult
Lentivirally Redirected CD123 Autologous T Cells in AML
Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and…
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia, Refractory
- Trial name
- NCT03766126
- Testing
- CART123 cells; cyclophosphamide; fludarabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pennsylvania
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
A Phase I/IIa, open-label, uncontrolled study to evaluate the safety and efficacy of Astarabine (BST-236) as single agent in patients with refractory or relapsed Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)…
- Trial name
- BSTPHASE1-01 (NCT02544438)
- Testing
- Astarabine (BST-236)
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- BioSight Ltd.
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
This phase I trial is studying the side effects and best dose of tipifarnib and bortezomib in treating patients with acute leukemia or chronic myelogenous leukemia in blast phase.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
- Trial name
- NCT00383474
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Tipifarnib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Leukemia
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
The purpose of this study is to evaluate both the efficacy and toxicity of infusional arsenic trioxide in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APML).
- Trial name
- NCT00008697
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory
A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)
Purpose/Specific Aims The study will determine if there is a reduction in malignant cell burden when patients with relapsed and/or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) consume tea made from the dried…
- Trial name
- Soursop (NCT07771803)
- Testing
- Soursop tea
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roger Strair
Leukemia, Lymphoma
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
RATIONALE: Biological therapy using growth factors may be effective in reducing side effects in patients who have hematologic cancer and are receiving radiation therapy, chemotherapy, and peripheral stem cell transplantation.
- Conditions
- Leukemia, Lymphoma, Oral Complications
- Trial name
- NCT00004061
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia
Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
The purpose of this study is to evaluate the long-term efficacy and safety profile of tosedostat in elderly patients suffering from refractory or relapsed Acute Myeloid Leukemia.
- Trial name
- NCT01180426
- Testing
- CHR-2797
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Chroma Therapeutics
Acute Myeloid Leukemia
Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML
This is a Phase I study with the goals of determining the feasibility, safety, and toxicity of administering sertraline in combination with timed-sequential cytosine arabinoside (ara-C) in adults with relapsed and refractory…
- Trial name
- NCT02891278
- Testing
- Sertraline, Cytosine arabinoside, allogeneic stem cell transplantation
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase Ib trial studies the side effects and best dose of nivolumab and ipilimumab after donor stem cell transplant in treating patients with high risk acute myeloid leukemia or myelodysplastic syndrome that does not respond…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03600155
- Testing
- Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Cancer, Relapse Leukemia
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
This study will evaluate the safety of infusing an anti-MiHA T cell line in patients suffering from an hematologic malignancy that has relapsed following hematopoietic stem cell transplantation from a matched donor.
- Conditions
- Hematologic Cancer, Relapse Leukemia, Relapsed Adult ALL, Relapsed Adult AML
- Trial name
- GLIDE (NCT03091933)
- Testing
- GLIDE
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in…
- Trial name
- NCT04951778
- Testing
- CC-91633
- Where
- 9 sites in United States, Spain
- Volunteers
- 56 people
- Sponsor
- Celgene
Leukemia
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00049179
- Testing
- cytarabine, gemtuzumab ozogamicin
- Where
- 151 sites in United States
- Volunteers
- 33 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.